I 型糖尿病 z-bo 2020-10-19 308

　　Researchers at St. Louis University School of Medicine in the United States recently discovered a new method to prevent type I diabetes and successfully tested it in mice. Type I diabetes is a chronic autoimmune disease, and many types of immune T cells have been confirmed to participate in the development of type I diabetes. The role of TH17 cells, one of the T cells, is controversial. In order to understand the specific role of TH17 cells, researchers at Saint Louis University School of Medicine synthesized a high-affinity ligand SR1001, which selectively stimulates two important nuclear receptors, which can regulate the development and development of TH17 cells. Features. It has achieved the purpose of inhibiting the differentiation and function of TH17 cells through RORα and RORγ.

　　In the experiment, in the early stage, after continuous injection of SR1001 in non-obese diabetic mice, the incidence of type I diabetes dropped to zero, while the incidence of type I diabetes in the control group was 70%. I found that I did it! Dr. Burris of the research group did not observe that any mice in the experimental group developed type I diabetes after receiving the injection, even if the islet B cells were significantly damaged before the injection. In the late stage of injection, even if significant immune infiltration was observed in the pancreas sections of the mice, compared with the control group, a large number of islet B cells were still retained, and the expression of insulin in the cells was also significantly increased. These results indicate that the inhibition of ROR function plays an important role in the protection of pancreatic islet B cells in an autoimmune environment.

　　Why does SR1001 have this effect? Subsequent studies have shown that SR1001 can inhibit the immune infiltration of the pancreas, reduce the formation of autoimmune antibodies against islet B cells, and more importantly, can interfere with the expression of various pro-inflammatory cytokines. display. Dr. Barris believes that ROR inhibitors can slow the progression of type I diabetes and even replace insulin therapy. The development of OR inhibitors proved to provide another possibility for the prevention or treatment of type I diabetes.